IOVA

Iovance Biotherapeutics Inc

IOVA, USA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

https://www.iovance.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IOVA
stock
IOVA

How Investors Are Reacting To Iovance Biotherapeutics (IOVA) FDA Boost For Its TIL Cancer Platform simplywall.st

Read more →
IOVA
stock
IOVA

Assessing Iovance Biotherapeutics (IOVA) Valuation After Clinical Trial Progress And New FDA Designations simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$8.35

Analyst Picks

Strong Buy

5

Buy

3

Hold

4

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.39

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.08 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-132.75 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.29

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 60.99% of the total shares of Iovance Biotherapeutics Inc

1.

Mhr Fund Management Llc

(8.0052%)

since

2025/06/30

2.

Vanguard Group Inc

(6.93%)

since

2025/06/30

3.

BlackRock Inc

(6.4216%)

since

2025/06/30

4.

Long Focus Capital Management, LLC

(3.2665%)

since

2025/06/30

5.

State Street Corp

(2.7333%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.6729%)

since

2025/07/31

7.

Millennium Management LLC

(2.5785%)

since

2025/06/30

8.

Invenomic Capital Management, LP

(2.2923%)

since

2025/06/30

9.

Morgan Stanley - Brokerage Accounts

(1.7827%)

since

2025/06/30

10.

Geode Capital Management, LLC

(1.7104%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(1.7091%)

since

2025/08/31

12.

Renaissance Technologies Corp

(1.3506%)

since

2025/06/30

13.

Goldman Sachs Group Inc

(1.3127%)

since

2025/06/30

14.

Two Sigma Investments LLC

(1.2805%)

since

2025/06/30

15.

Principal Financial Group Inc

(1.2716%)

since

2025/06/30

16.

Citadel Advisors Llc

(1.1368%)

since

2025/06/30

17.

Bank of America Corp

(1.1136%)

since

2025/06/30

18.

Vanguard Small Cap Index

(1.0076%)

since

2025/07/31

19.

SPDR® S&P Biotech ETF

(0.9847%)

since

2025/08/31

20.

Palo Alto Investors, LLC

(0.9477%)

since

2025/06/30

21.

Invenomic Institutional

(0.9065%)

since

2025/04/30

22.

Soleus Capital Management, L.P.

(0.9014%)

since

2025/06/30

23.

Dimensional Fund Advisors, Inc.

(0.8094%)

since

2025/06/30

24.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7454%)

since

2025/07/31

25.

Fidelity Small Cap Index

(0.7141%)

since

2025/06/30

26.

Royal Bank of Canada

(0.6575%)

since

2025/06/30

27.

Vanguard Small Cap Value Index Inv

(0.6468%)

since

2025/07/31

28.

Orion Investment Co

(0.6463%)

since

2025/06/30

29.

iShares Russell 2000 Value ETF

(0.6145%)

since

2025/08/31

30.

Principal U.S. Small Cap Equity

(0.6054%)

since

2025/06/30

31.

iShares Biotechnology ETF

(0.4506%)

since

2025/08/31

32.

Principal SmallCap R5

(0.4128%)

since

2025/07/31

33.

Fidelity Extended Market Index

(0.3712%)

since

2025/07/31

34.

C WorldWide Healthcare Select 1A

(0.3482%)

since

2025/07/31

35.

Vanguard Russell 2000 ETF

(0.3342%)

since

2025/07/31

36.

Schwab US Small-Cap ETFâ„¢

(0.3207%)

since

2025/08/30

37.

JPM Thematics Genetic Thrps C2 dist USD

(0.2733%)

since

2025/07/31

38.

State St Russell Sm Cap® Indx SL Cl I

(0.2591%)

since

2025/08/31

39.

Vanguard Explorer Inv

(0.2383%)

since

2025/06/30

40.

Vanguard Health Care ETF

(0.2241%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.25

EPS Estimate

-0.2617

EPS Difference

0.0117

Surprise Percent

4.4708%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.